Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with Crizotinib or Lorlatinib in advanced NSCLC
NCT02584634Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2015
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of avelumab in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Dec 2015; status: terminated.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02584634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584634.